TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03806309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
Study: NCT02134171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological and imaging investigations
Description: From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
Study: NCT02394054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study: NCT02956109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone (BAY94-8862): 1 0mg tablet
Description: 10 mg finerenone immediate-release tablet; single dose in the fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets
Description: 5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
Description: 1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
Description: 1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
Study: NCT03848975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training for ECV
Description: Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training for VE
Description: Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
Study: NCT04213807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 1
Description: Subcutaneous injection: low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 2
Description: Subcutaneous injection: high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAA868 Cohort 3
Description: Subcutaneous injection: Dose to be determined.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection: Placebo
Study: NCT03263611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intradiscal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG0103
Description: single intradiscal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG0103
Description: single intradiscal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG0103
Description: single intradiscal injection
Study: NCT00955162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine (Subutex)
Description: Sublingual tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Description: Sublingual tablet
Study: NCT03926026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: NCX 4251 Ophthalmic Suspension, 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: NCX 4251 Ophthalmic Suspension, 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NCX 4251 Ophthalmic Suspension, 0%
Study: NCT01807676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Double Lumen Tube
Study: NCT03163121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
Study: NCT03926026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NCX 4251 Ophthalmic Suspension, 0%
Study: NCT01411137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066
Description: Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules
Study: NCT00569634

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venous blood gas analysis
Description: When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
Study: NCT01558908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of ERC
Description: Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
Study: NCT04017611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00038
Description: Noninvasive regional oximeter
Study: NCT04580004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Optimization Arm
Description: An evidence-based medication recommendation website that is provided to the patients.
Study: NCT02829398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CerebroSpinal fluid and plasma samples
Description: CerebroSpinal fluid and plasma samples for biological markers

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CerebroSpinal fluid and plasma samples
Description: CerebroSpinal fluid and plasma samples for biological markers
Study: NCT01128595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/GW642444M
Study: NCT03163121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine
Description: Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride
Study: NCT01128595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01841671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV
Description: As indicated

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV
Description: As indicated
Study: NCT01841671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mOPV type 2
Description: Administered at 28 weeks of age to all study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV type 2
Description: Administered at 28 weeks of age to all study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV type 2
Description: Administered at 28 weeks of age to all study participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
Study: NCT03163121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mosquito-bite CHMI
Description: Bites of 5 infected mosquitoes of NF54 strain
Study: NCT03848208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet
Study: NCT02706795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA
Description: Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
Study: NCT00439309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam/Thrombin
Description: Gelfoam/Thrombin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuSeal
Description: VascuSeal
Study: NCT02227290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftin Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study: NCT02270190

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Study: NCT03848208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo oral tablet
Study: NCT04820634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wonderworks
Description: The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
Study: NCT02241330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified wheat
Description: Wheat was grown by foliar Zn application and is therefore biofortified

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortification
Description: Wheat flour is fortified before testmeal preparation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: wheat flour is used as control comparator.
Study: NCT03826173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPPA
Description: The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA
Description: The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
Study: NCT02562508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 doses of HPV 16/18 bivalent vaccine
Description: Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
Study: NCT00820482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur®, Ferring
Description: 75 UI/day of Hp-hMG (Menopur®)
Study: NCT01841671

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
Study: NCT01064999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
Study: NCT00820482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH (Gonal®,
Description: 75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
Study: NCT01175356

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iobenguane I-131
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02382276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene hydrochloride
Study: NCT01175356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04217473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILT-123
Description: TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
Study: NCT02983695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL-TC150
Description: The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
Study: NCT01649752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter
Study: NCT00011362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Early
Description: Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Early
Description: Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Late
Description: Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Late
Description: Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
Study: NCT01778049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: Empagliflozin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Empagliflozin active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: Empagliflozin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 / BI 1356 Placebo
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Study: NCT01649752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.